Kiora Pharmaceuticals, Inc. ((KPRX)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kiora Pharmaceuticals, Inc. is conducting a Phase I/II clinical study titled ‘A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)’. The primary goal is to evaluate the safety, tolerability, and efficacy of KIO-301, a promising treatment for retinitis pigmentosa and choroideremia, potentially offering new hope for patients with these degenerative eye conditions.
The intervention being tested is KIO-301, a drug administered via intravitreal injection. This treatment aims to address the underlying causes of vision loss associated with retinitis pigmentosa and choroideremia.
The study follows an interventional, open-label design with a single-group assignment. There is no masking involved, and the primary purpose is treatment, focusing on the effects of KIO-301 on the targeted conditions.
The study began on March 8, 2022, and is currently recruiting participants. The last update was submitted on September 2, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and potential market entry.
The update on this study could positively influence Kiora Pharmaceuticals’ stock performance by enhancing investor confidence in the company’s innovative pipeline. As the study progresses, it may also impact the competitive landscape in the treatment of retinal diseases.
The study is ongoing, with further details available on the ClinicalTrials portal.